A multiple center, randomized, double blind, parallel group, multiple oral doses study to evaluate the pharmacokinetic and pharmacodynamic profiles of 150 mg and 300 mg of SPP100 [aliskiren] in Japanese patients with mild to moderate essential hypertension
Phase of Trial: Phase I
Latest Information Update: 28 Nov 2007
At a glance
- Drugs Aliskiren (Primary)
- Indications Essential hypertension
- Focus Biomarker; Pharmacodynamics; Pharmacokinetics
- Sponsors Novartis
- 28 Nov 2007 Status change from recruiting to completed.
- 12 Feb 2007 New trial record.